8 December 2016 - Sanofi and Regeneron Pharmaceuticals today announced that the EMA has accepted for review the marketing authorisation application for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. 

The investigational biologic therapy Dupixent inhibits signalling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response, which is believed to be a major driver in the pathogenesis of the disease.

Read Sanofi press release